Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

3.0K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
3.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

278
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
278
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

711
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
711
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

786
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
786
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

219
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
219
The Blood-brain Barrier00:49

The Blood-brain Barrier

49.5K
Overview
49.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles.

European journal of immunology·2026
Same author

Dysregulation of complement at the synapse in P301S mice and human tauopathies.

Acta neuropathologica communications·2026
Same author

Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis.

Med (New York, N.Y.)·2026
Same author

Activation of the Lectin Pathway Drives Persistent Complement Dysregulation in Long COVID.

Immunology·2026
Same author

Absence of complement terminal pathway activity in C6-deficient mice prolongs survival in a mouse model of severe malarial infection.

Immunobiology·2025
Same author

Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors.

Science advances·2025

Related Experiment Video

Updated: Sep 30, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K

Targeting complement in neurodegeneration: challenges, risks, and strategies.

Wioleta M Zelek1, B Paul Morgan1

  • 1UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF24 4HR, UK.

Trends in Pharmacological Sciences
|March 11, 2022
PubMed
Summary

Complement drives neuroinflammation and neurodegenerative diseases (NDDs). New anticomplement drugs are needed to enter the central nervous system (CNS) for effective NDD treatment.

Keywords:
blood–brain barriercomplementdrugsneurodegenerationneuroinflammation

More Related Videos

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

7.1K
Strategies for Study of Neuroprotection from Cold-preconditioning
16:27

Strategies for Study of Neuroprotection from Cold-preconditioning

Published on: September 2, 2010

15.0K

Related Experiment Videos

Last Updated: Sep 30, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K
A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

7.1K
Strategies for Study of Neuroprotection from Cold-preconditioning
16:27

Strategies for Study of Neuroprotection from Cold-preconditioning

Published on: September 2, 2010

15.0K

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Accumulating evidence implicates the complement system in driving neuroinflammation and neurodegenerative diseases (NDDs).
  • Interest in complement-modulating drugs has surged, initially for rare diseases, now expanding to common NDDs where complement plays a role.

Purpose of the Study:

  • To summarize evidence linking complement to neurodegeneration.
  • To advocate for testing anticomplement drugs in NDDs.
  • To discuss strategies for developing CNS-penetrant anticomplement therapies.

Main Methods:

  • Review of scientific literature on complement's role in neurodegeneration.
  • Analysis of current anticomplement drug development landscape.
  • Discussion of drug design principles for CNS penetration.

Main Results:

  • The complement system is a key factor in the pathology of diverse neurodegenerative diseases.
  • Current anticomplement drugs lack central nervous system (CNS) penetration, limiting their use in NDDs.
  • There is a therapeutic gap for anticomplement drugs targeting neurodegeneration.

Conclusions:

  • Anticomplement therapies hold promise for treating neurodegenerative diseases.
  • Development of CNS-penetrant anticomplement drugs is crucial.
  • Further research and drug design are needed to target complement in the CNS for NDDs.